Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11901548 | 0.88 | ALDH1A1 (0.51) | ALDH1A1HTTRAB9ATDP1ATM | |
| SCHEMBL2501948 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HTTRAB9ASMN1; SMN2TDP1 | |
| SCHEMBL11901468 | 0.79 | HTT (0.61) | ALDH1A1HTTRAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2508268 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HTTRAB9ATDP1ATM | |
| SCHEMBL30378593 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HTTRAB9ATDP1ATM | |
| SCHEMBL2507274 | 0.77 | EPAS1 (0.58) | ALDH1A1HTTRAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2503071 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HTTRAB9ATDP1ATM | |
| SCHEMBL11900742 | 0.77 | ALDH1A1 (0.51) | ALDH1A1HTTRAB9ATDP1ATM | |
| SCHEMBL16487061 | 0.76 | L3MBTL1 (0.60) | ALDH1A1HTTSMN1; SMN2TDP1GAA | |
| SCHEMBL31144749 | 0.76 | ALDH1A1 (0.54) | ALDH1A1HTTRAB9ATDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2552908-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123751-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ALDH1A1 3905/4885HTT 1338/4885RAB9A 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.